OBJECTIVE: The identification of sex-based disparities in the use of effective medications in high-risk populations can lead to interventions to minimize disparities in health outcomes. The objective of this study was to determine sex-specific rates of cardioprotective medication use in a large population-level administrative-health database from a universal-payer environment. RESEARCH DESIGN AND METHODS: This observational, population-based cohort study used provincial administrative data to compare the utilization of cardioprotective medications between @entity1 and @entity1 in the first year following a @entity6 diagnosis. Competing risks regression was used to calculate crude and adjusted sub-hazard ratios for time-to-first angiotensin-converting-enzyme inhibitor, angiotensin receptor blocker, or statin dispensations. RESULTS: There were 15,120 (45.4%) @entity1 and 18,174 (54.6%) @entity1 with @entity6 in the study cohort. Overall cardioprotective medication use was low for both primary and secondary prevention for both @entity1 and @entity1 . In the year following a @entity6 diagnosis, @entity1 were less likely to use a statin relative to @entity1 (adjusted sub-hazard ratio [aSHR] 0.90, 95% confidence interval [CI] 0.85 to 0.96), angiotensin-converting-enzyme inhibitors (aSHR 0.90, 95% CI 0.86 to 0.94), or any cardioprotective medication (aSHR 0.93, 95% CI 0.90 to 0.97). CONCLUSIONS: Cardioprotective medication use was not optimal in @entity1 or @entity1 . We also identified a health care gap with cardioprotective medication use being lower in @entity1 with @entity6 compared to @entity1 . Closing this gap has the potential to reduce the impact of @entity65 in @entity1 with @entity6 .

Sex-based disparities in cardioprotective medication use in adults with XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'men'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
